Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Airborne Pathogens
$8.4M NIH biodefense grants to be used for development of vaccines
October 27th, 2003
Dynavax Technologies announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health, has awarded the company three biodefense grants totaling $8.4 million to support the development of novel products for the prevention and treatment of infectious diseases that could result from an act of terrorism or war. The three grants will be applied to the development of infectious disease products based on Dynavax's second-generation ImmunoStimulatory DNA Sequences (ISS) technology, including an improved anthrax vaccine for providing rapid protective immunity, a novel influenza vaccine for controlling a pandemic flu...
Source: Health & Medicine Week (2003-10-27)
|
